Skip to main content

Inflammation; Skin

0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Erythromycin 4% topical gel formulation:N/A
Maruho
MaruhoJapan - Osaka
1 program
Erythromycin 4% topical gel formulation:N/A1 trial
Active Trials
NCT03779360Completed32Est. Feb 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MaruhoErythromycin 4% topical gel formulation:

Clinical Trials (1)

Total enrollment: 32 patients across 1 trials

NCT03779360MaruhoErythromycin 4% topical gel formulation:

Intradermal LPS and Antibiotics

Start: Oct 2018Est. completion: Feb 201932 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.